Maravai Lifesciences (MRVI) reported $186M in revenue for fiscal 2025, −28.3% year on year. That ranks #2691 by revenue among 2853 SEC filers and #291 in Healthcare. It posted a net loss of −$131M for the same year. Revenue has grown 4.4% a year on average since 2019 ($143M then). The fiscal 2025 balance sheet shows $771M in total assets, $217M in cash and $286M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $186M | −28.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $34.0M | −68.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$215M | +$20.4M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$131M | +$14.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$57.6M | −$65.0M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $13.1M | −55.7% | FY20252025-12-31 |
| Total assetsAssets | $771M | −23.6% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $212M | −34.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $217M | −32.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $286M | −1.4% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $65.8M | −$3.7M | Open → |
| Q2 20262026-06-30 | $51.4M | −$12.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Maravai Lifesciences Holdings, Inc.
- Ticker
- MRVI
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001823239
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Lakeland IndustriesLAKE | $193M | −$25.3M |
| BioteBTMD | $192M | $27.0M |
| Rhythm PharmaceuticalsRYTM | $190M | −$196,539 |
| Maravai LifesciencesMRVI | $186M | −$131M |
| Stoke TherapeuticsSTOK | $184M | −$6.9M |
| Glass House BrandsGLAS | $182M | −$29.7M |
| KamadaKMDA | $180M | $20.2M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Maravai Lifesciences — Key figures |url=https://companiesranked.com/en/company/maravai-lifesciences |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Maravai Lifesciences — Key figures. CompaniesRanked. https://companiesranked.com/en/company/maravai-lifesciencesBibTeX
@misc{companiesranked-en-company-maravai-lifesciences-2026,
author = {{CompaniesRanked}},
title = {{Maravai Lifesciences — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/maravai-lifesciences}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001823239-26-000011 · February 26, 2026
{{cite web |title=Maravai Lifesciences — Key figures — 10-K (0001823239-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/mrvi-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.